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Abstract
Objective:  To  compare  the  efﬁcacy  of  intravenous  ibuprofen  at  high  (20-10-10  mg/kg/dose)  and
low doses  (10-5-5  mg/kg/dose)  the  closure  of  patent  ductus  arteriosus  in  preterm  newborns.
Methods:  A  cohort  study  with  historical  control  of  newborns  that  received  high-  and  low-dose
intravenous  ibuprofen,  from  2010  to  2013  in  a  neonatal  intensive  care  unit,  for  closure  of  the
patent ductus  arteriosus,  documented  by  echocardiography.  Secondary  outcomes  included  the
number of  ibuprofen  cycles,  incidence  of  bronchopulmonary  dysplasia,  necrotizing  enterocoli-
tis, changes  in  renal  function,  and  death.
Results:  Seventy-seven  patients  received  three  doses  of  ibuprofen  for  the  treatment  of  patent
ductus arteriosus,  with  33  receiving  high-dose  and  44  low-dose  therapy.  The  ductus  closed  after
the ﬁrst  cycle  in  25  (56.8%)  low-dose  patients  and  in  17  (51.5%)  high-dose  patients  (p  >  0.99).
Sixteen patients  received  a  second  cycle  of  ibuprofen,  and  the  ductus  closed  in  50%  after
low-dose and  in  60%  after  high-dose  therapy  (p  >  0.99).  Seven  patients  required  surgery  for
ductus closure,  13.6%  in  the  low-dose  group  and  3%  in  the  high-dose  group  (p  =  0.22).  Thirty-
nine patients  developed  bronchopulmonary  dysplasia,  50%  in  the  low-dose  group  and  51.5%  in
the high-dose  group  (p  >  0.99).  Twenty-two  (50%)  low-dose  patients  died  vs.  15  (45.5%)  high-dose
patients (p  =  0.86).
Conclusions:  There  was  no  difference  in  closure  of  the  ductus  arteriosus  or  occurrence  of
adverse effects  between  the  two  dose  regimens.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
 Please cite this article as: Dornelles LV, Corso AL, Silveira RC, Procianoy RS. Comparison of two dose regimens of ibuprofen for the closure
f patent ductus arteriosus in preterm newborns. J Pediatr (Rio J). 2016;92:314--8.
 The study is associated with the Neonatology Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
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Comparac¸ão  de  dois  esquemas  posológicos  de  ibuprofeno  para  o  fechamento  do  canal
arterial  em  recém-nascidos  pré-termo
Resumo
Objetivo:  Comparar  a  eﬁcácia  do  ibuprofeno  endovenoso  em  doses  altas  (20,  10  e
10 mg/kg/dose)  e  em  doses  baixas  (10,  5  e  5  mg/kg/dose)  para  o  fechamento  do  canal  arterial
em recém-nascidos  pré-termo.
Métodos:  Estudo  de  coorte  com  controle  histórico  pesquisando  recém-nascidos  que  receberam
ibuprofeno  endovenoso,  no  período  de  2010  à  2013  na  unidade  de  internac¸ão  neonatal,  em
doses altas  e  baixas  para  o  fechamento  do  canal  arterial,  documentado  por  ecocardiograma.
Como desfechos  secundários  foram  avaliados  o  número  de  ciclos  de  ibuprofeno  realizados,  a
incidência de  displasia  broncopulmonar,  enterocolite  necrosante,  alterac¸ão  de  func¸ão  renal  e
óbito.
Resultados:  77  pacientes  receberam  3  doses  de  ibuprofeno  para  tratamento  do  canal  arterial,
sendo que  33  dose  alta  e  44  dose  baixa.  25  (56.8%)  dos  que  receberam  dose  baixa  fecharam  o
canal após  o  1◦ ciclo  e  17  (51,5%)  fecharam  após  receberem  dose  alta  (p  >  0.99).  16  pacientes
receberam  o  2◦ ciclo,  destes  50%  fecharam  o  canal  após  uso  de  dose  baixa  e  60%  após  o  uso
de dose  alta  (p  >  0.99).  7  pacientes  foram  à  cirurgia  para  fechamento  do  canal,  sendo  13,6%  do
grupo que  recebeu  dose  baixa  e  3%  dose  alta  (p  =  0.22).  39  pacientes  desenvolveram  displasia
broncopulmonar,  50%  do  grupo  de  dose  baixa  e  51,5%  do  grupo  de  dose  alta  (p  >  0.99).  22  (50%)
dos pacientes  do  grupo  dose  baixa  evoluiu  a  óbito  versus  15  (45,5%)  dos  pacientes  do  grupo  de
dose alta  (p  =  0.86).
Conclusão:  Não  encontramos  diferenc¸a  em  relac¸ão  ao  fechamento  do  canal  arterial,  assim  como
ocorrência de  efeitos  adversos,  quando  comparamos  os  dois  esquemas  posológicos.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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aIntroduction
Patent  ductus  arteriosus  (PDA)  is  the  most  common  car-
diac  abnormality  in  preterm  newborns,  especially  those
under  28  weeks  old  of  gestational  age.1 This  alteration
causes  a  left-right  shunt  through  the  ductus  arteriosus
and  can  become  clinically  evident.  When  symptomatic,  it
increases  the  need  for  ventilatory  support,  increases  the
risk  of  peri-intraventricular  hemorrhage,2 of  bronchopul-
monary  dysplasia  (BPD)3,4 and  necrotizing  enterocolitis,5
and  reduces  survival  rates.6 However,  there  is  no  clear
evidence  of  the  long-term  results  of  PDA  treatment.7
Several  randomized  controlled  trials  have  failed  to  show
any  beneﬁt  from  treatment  on  survival  and  long-term
outcomes.1,8,9
A  more  conservative  approach  has  been  increasingly  sug-
gested,  especially  in  patients  with  good  clinical  evolution.
This  is  due  to  the  high  chance  of  spontaneous  closure,  more
common  in  newborns  weighing  >800  g,  without  the  need  for
mechanical  ventilation  and  with  no  signs  of  heart  failure  or
pulmonary  congestion.10,11
In  patients  whose  patent  ductus  arteriosus  becomes
clinically  relevant  and  symptomatic,  its  constriction  can
be  induced  with  cyclooxygenase  inhibitors,  such  as
indomethacin  and  ibuprofen,  with  permanent  closure  rates
of  around  60--80%.12--14 Both  have  side  effects,  but  ibuprofen
seems  to  have  fewer  negative  effects  on  the  cerebral  and
renal  blood  ﬂow  and  also  possibly  fewer  gastrointestinal  side
effects.15--17
M
A
iThe  recommended  standard  dose  of  intravenous  ibupro-
en  for  patent  ductus  arteriosus  closure  is  10  mg/kg/dose
n  the  ﬁrst  day  and  5  mg/kg/dose  on  the  second  and  third
ays.18,19 However,  Dani  et  al.16 demonstrated  that  the  use
f  ibuprofen  at  high  doses  (20-10-10  mg/kg/day)  is  more
ffective  than  the  standard  regimen  for  PDA  in  preterm  new-
orns  with  a  gestational  age  <29  weeks,  without  increasing
he  rate  of  adverse  effects.
From  the  year  2012,  aiming  to  achieve  higher  rates  of
DA  closure  in  preterm  newborns,  ibuprofen  dose  regimens
ere  changed  for  the  drug  treatment  of  PDA  in  the  Neonatal
ntensive  Care  Unit  of  Hospital  de  Clínicas  de  Porto  Alegre
HCPA).  Higher  doses  of  ibuprofen  started  to  be  utilized,
ather  than  the  previously  used  standard  dose.  Therefore,
he  doses  changed  to  20  mg/kg  of  ibuprofen  for  the  ﬁrst
ntravenous  infusion  on  day  1,  followed  by  10  mg/kg  on  days
 and  3,  when  newborns  showed  a hemodynamically  signiﬁ-
ant  ductus  arteriosus  conﬁrmed  by  the  echocardiography.
This  study  aims  to  compare  the  therapeutic  effectiveness
nd  the  impact  of  the  two  ibuprofen  doses  on  PDA  closure
ates  in  preterm  newborns,  as  well  as  other  morbidities  such
s  BPD,  renal  impairment,  need  for  surgery  for  PDA  closure,
nd  death.ethods
 cohort  study  with  historical  control  was  performed.  It
ncluded  all  preterm  newborns  who  received  intravenous
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buprofen  in  the  period  of  January  2010  to  December  2013
or  the  treatment  of  patent  ductus  arteriosus  in  the  Neona-
ology  Service  of  HCPA.  The  HCPA  is  a  university  tertiary
eferral  hospital  with  the  capacity  to  admit  up  to  50  new-
orns.  It  has  20  neonatal  intensive  care  unit  (NICU)  beds,
hich  encompass  less  complex  cases  to  extremely  preterm
ewborns  and  those  with  rare  diseases.  The  study  was
pproved  by  the  ethics  committee  of  the  institution.
The  population  was  divided  into  two  groups,  one  receiv-
ng  low-dose  ibuprofen  (10-5-5  mg/kg/day  --  single  daily
ose),  treated  before  the  change  in  dose  regimens  and  those
eceiving  high-dose  ibuprofen  (20-10-10  mg/kg/day  --  single
aily  dose)  for  three  days,  treated  after  the  change  in  the
are  protocol.
All  patients  underwent  echocardiography  for  the  diagno-
is  of  PDA.  Treatment  was  indicated  for  those  with  signiﬁcant
linical  signs  and  presence  of  respiratory  symptoms,  and
ith  echocardiography  ﬁndings  showing  left-right  shunt
hrough  the  ductus  arteriosus  with  left  atrium/aortic  root
atio  ≥1.5  mm.
Newborns  with  congenital  heart  malformation,  those
ithout  an  echocardiogram  to  conﬁrm  the  diagnosis,  and
hose  who  did  not  complete  the  treatment  due  to  clinical
nstability  or  death  were  excluded.
The  collected  demographic  data  included  gestational
ge,  birth  weight,  days  of  life  at  the  beginning  of  treatment,
eed  for  other  ibuprofen  treatment  cycles,  need  for  surgical
losure,  death,  and  neonatal  morbidities,  such  as  bron-
hopulmonary  dysplasia  (deﬁned  as  need  for  supplemental
xygen  or  ventilatory  support  at  28  days  of  life),  necrotizing
nterocolitis  (presence  of  pneumatosis  or  intestinal  perfo-
ation),  need  for  ventilatory  support  (continuous  positive
irway  pressure  [CPAP],  noninvasive  mechanical  ventilation
NIMV],  mechanical  ventilation  [MV],  and  high-frequency
entilation  [HFV]),  presence  of  chorioamnionitis,  sepsis  with
ositive  blood  cultures,  and  peri-intraventricular  hemor-
hage  grades  III  and  IV.  Serum  creatinine  and  urea  levels  48  h
efore  and  after  completion  of  each  treatment  cycle  were
lso  recorded.
The  closure  of  the  patent  ductus  arteriosus,  the  primary
utcome,  was  deﬁned  as  complete  PDA  closure  observed  on
chocardiography.
This  study  compared  the  clinical  outcome  of  patients
eceiving  higher  doses  of  ibuprofen  with  those  previously
reated  with  lower  doses.
tatistical analysis
ample  size  calculation
o  detect  a  difference  of  30  percentage  points  (from  40%  to
0%  of  ductus  arteriosus  closure  failure),  considering  power
f  80%  and  ˛  =  0.05,  32  patients  were  necessary  in  each
roup.
tatistical  testsata  were  stored  in  a  database  created  with  the  software
PSS® version  18.0  (SPSS  Inc.  Released  2009.  PASW  Statistics
or  Windows,  Version  18.0  IL,  USA),  which  was  also  used  for
n
(
p
(Dornelles  LV  et  al.
tatistical  analyses.  Categorical  variables  were  described  as
bsolute  and  relative  frequencies,  continuous  variables  with
ymmetrical  distribution  as  mean  and  standard  deviation,
nd  the  asymmetrical  variables  as  median  and  interquartile
ange.  Categorical  variables  were  compared  using  Fisher’s
xact  test,  the  quantitative  variables  with  symmetrical  dis-
ribution  by  Student’s  t-test,  and  those  with  asymmetrical
istribution  by  the  Mann--Whitney  test.  The  signiﬁcance
evel  was  set  at  0.05.
The  study  was  approved  by  the  institutional  research
ommittee,  and  all  researchers  signed  a consent  form  in
rder  to  obtain  access  to  patients’  medical  records,  in  which
hey  swore  to  maintain  complete  conﬁdentiality.
esults
 total  of  84  patients  received  ibuprofen  for  PDA  closure
n  the  abovementioned  period;  seven  were  excluded,  three
ecause  they  received  ﬁve  ibuprofen  doses  rather  than
ne  or  two  cycles  of  three  doses,  and  four  patients  due
o  the  incomplete  treatment  because  of  death  or  major
linical  instability.  There  were  no  losses  due  to  cardiac
alformations  or  lack  of  diagnosis  on  echocardiography.
he  percentage  of  losses  was  8.3%.  The  study  population
onsisted  of  77  patients,  of  whom  33  (42.8%)  received  high-
ose  and  44  (57.1%)  low-dose  ibuprofen.
There  was  no  signiﬁcant  difference  between  the  two
roups  regarding  birth  weight  (p  =  0.32),  gestational  age
p  =  0.49),  days  of  life  at  the  beginning  of  the  treatment
ith  ibuprofen  (p  =  0.32),  chorioamnionitis  (p =  0.62),  need
or  mechanical  ventilation  (p  =  0.74),  necrotizing  enterocol-
tis  (p  =  0.76),  peri-intraventricular  hemorrhage  (p  >  0.99),
yaline  membrane  disease  (p  =  0.06),  and  infection  with  a
ositive  culture  (p  =  0.71)  (Table  1).
Among  those  who  received  low-dose  treatment,  25
56.8%)  had  PDA  closure  after  the  ﬁrst  cycle  of  ibuprofen  and
7  (51.5%)  after  receiving  high-dose  treatment  (p  >  0.99).  A
otal  of  22.7%  of  the  patients  in  the  low-dose  group  received
 second  cycle  vs.  18.2%  of  patients  in  the  high-dose  group
p  =  0.63).
Sixteen  patients  received  a  second  ibuprofen  cycle,  but
nly  13  were  submitted  to  an  echocardiogram  at  the  end
f  treatment;  eight  patients  from  the  low-dose  group  and
ve  from  the  high-dose  group.  Four  patients  (50%)  had  PDA
losure  after  the  low-dose  and  three  (60%)  after  the  high-
ose  treatment  (p  >  0.99).
Regarding  the  secondary  outcomes,  seven  patients
nderwent  surgery  for  PDA  closure;  13.6%  in  the  low-dose
nd  3%  in  the  high-dose  group  (p  =  0.22).  A  total  of  53
atients  (68.8%)  were  assessed  on  the  28th  day  of  life  for
ronchopulmonary  dysplasia;  30  from  the  low-dose  and  23
rom  the  high-dose  group.  Twenty-two  patients  from  the
ow-dose  and  17  from  the  high-dose  group  developed  BPD
p  >  0.99);  22  (50%)  patients  from  the  low-dose  group  died
s.  15  (45.5%)  patients  from  the  high-dose  group  (p  =  0.86).
rea  and  creatinine  levels  after  the  ﬁrst  cycle  showed
o  statistically  signiﬁcant  differences  between  the  groups
p  =  0.62  for  urea  and  p  =  0.29  for  creatinine)  and  only  one
atient  had  oliguria,  which  was  from  the  low-dose  group
Table  2).
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Table  1  Characteristics  of  the  studied  patients.
Low  dose  group  High  dose  group  p
(n =  44)  (n  =  33)
GA  (weeks)a 27.9  (±3.3)  27.4  (±2.9)  0.49
BW (grams)a 1002  (±428) 913  (±321) 0.32
Start of  treatment  (DL)b 2  (2--4)  3  (2--4)  0.32
RDSc 42  (95.5%)  27  (81.8%)  0.06
Chorioamnionitisc 10  (22.7%)  10  (30.3%)  0.62
Sepsisc 19  (43.2%)  12  (36.4%)  0.71
Ventilatory supportc 43  (97.7%)  32  (97%)  0.74
NECc 7  (15.9%)  7  (21.2%)  0.76
PIVHc 9  (20.5%)  7  (21.2%)  >0.99
GA, gestational age; BW, birth weight; DL, days of life; RDS, respiratory distress syndrome; sepsis, presence of positive blood culture;
NEC, necrotizing enterocolitis; PIVH, peri-intraventricular hemorrhage.
a Student’s t-test (mean and standard deviation).
b Mann--Whitney test (median and interquartile range).
c Fisher’s exact test (frequency and percentage).
Table  2  Treatment  outcomes.
Low-dose  group  High-dose  group  p
(n =  44)  (n  =  33)
PDA  closed  after  1st  cyclea 25  (56.8%) 17  (51.5%)  >0.99
Received 2nd  cyclea 10  (22.7%) 6  (18.2%) 0.63
PDA closed  after  2nd  cyclea 4  (50%) 3  (60%)  >0.99
Ureab 84.2  ±  40.2 77.8  ±  48.9 0.62
Creatinineb 0.86  ±  0.44 0.74  ±  0.32 0.29
Oliguriaa 1  (2.3%) 0  (0%) >0.99
Surgerya 6  (13.6%) 1  (3%) 0.22
BPDa 22  (50%)  17  (51.5%)  >0.99
Deatha 22  (50%)  15  (45.5%)  0.86
PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia.
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ba Fisher’s exact test (frequency and percentage).
b Student’s t-test (mean and standard deviation).
Discussion
This  study  did  not  show  greater  efﬁciency  of  higher  doses
of  intravenous  ibuprofen  over  the  standard  dose  for  PDA
closure  in  preterm  newborns.  In  addition,  no  differences
were  found  regarding  the  occurrence  of  short-term  adverse
effects  or  neonatal  morbidities  when  the  two  regimens  were
compared.
The  optimal  dose  of  ibuprofen  for  PDA  treatment
remains  controversial.  The  standard  regimen  is  based  on
limited  and  scarce  pharmacokinetic  data.19--21 Desfrere
et  al.22 suggested  that  a  higher-dose  regimen,  with  20,  10,
10  mg/kg/day  for  three  days,  could  attain  higher  PDA  clo-
sure  rates  in  newborns  with  less  than  27  weeks  of  gestational
age;  however,  the  tolerability  and  safety  should  be  carefully
assessed  in  further  studies  before  being  routinely  recom-
mended.
Meißner  et  al.10 found  a  clear  trend  toward  higher  rates
of  PDA  closure  with  higher  doses  with  no  increase  in  adverse
effects,  but  without  statistical  signiﬁcance.
Hirt  et  al.  demonstrated  that,  with  the  increase  in
postnatal  age,  plasma  ibuprofen  clearance  also  increased,
resulting  in  a  reduction  of  half-life  (42.2  h  at  three  days
c
i
e
ds.  17.7  h  at  ﬁve  days),19 probably  due  to  the  maturation
f  cytochrome  P450,  which  metabolizes  ibuprofen.23 These
uthors  concluded  that  the  ibuprofen  dose  regimen  should
e  prospectively  tested.
Considering  the  hypothesis  that  the  increase  in  ibupro-
en  doses  for  PDA  closure  would  be  more  effective  than
he  standard  dose,  with  no  increase  in  adverse  events,
ani  et  al.  designed  a  randomized  controlled  study,  which
ssessed  70  newborns,  of  whom  35  received  the  standard
ose,  and  35,  the  double  dose.  The  authors  observed  that
he  high-dose  regimen  was  more  effective  for  PDA  closure
n  preterm  newborns  younger  than  27  weeks  of  gestational
ge,  with  no  increase  of  adverse  events  rates.16
In  disagreement  with  the  results  of  the  study  by  Dani
t  al.,16 the  use  of  high  doses  of  ibuprofen  in  the  present
nalysis  showed  no  signiﬁcant  difference  regarding  the
ncrease  in  PDA  closure  rates.  Additionally,  no  difference
egarding  the  effectiveness  of  the  second  cycle  of  treatment
etween  the  two  groups  was  found.  Although  not  statisti-
ally  signiﬁcant,  the  need  for  PDA  surgical  closure  was  higher
n  the  group  that  received  low  doses  of  ibuprofen.  How-
ver,  the  number  of  assessed  patients  was  not  sufﬁcient  to
eﬁnitely  analyze  this  outcome.
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This  study  showed  no  statistically  signiﬁcant  differences
egarding  neonatal  morbimortality,  such  as  the  presence
f  bronchopulmonary  dysplasia,  peri-intraventricular  hem-
rrhage,  necrotizing  enterocolitis,  and  death  between  the
roups  that  received  different  doses  of  ibuprofen.
Renal  failure  or  oliguria  has  been  reported  in  5--7%  of
atients  treated  with  ibuprofen  for  PDA  closure,  but  it  is
eversible.1 Among  the  patients  in  the  present  study,  only
ne  had  oliguria  and  this  patient  belonged  to  the  low-dose
roup.  The  administration  of  higher  doses  was  well  toler-
ted  and  patients  showed  no  adverse  effects.  There  was  no
igniﬁcant  difference  related  to  serum  levels  of  urea  and
reatinine  after  treatment  with  ibuprofen  between  the  two
roups.  These  ﬁndings  are  in  agreement  with  the  data  pre-
iously  published  in  the  literature,  which  reported  only  mild
dverse  effects.22
To  guarantee  the  safety  and  efﬁcacy  of  different  ibupro-
en  dose  regimens,  the  authors  emphasize  the  small  number
f  assessed  patients  as  a  limitation  of  this  study,  in  addition
o  its  retrospective  design.  However,  although  it  appears
easonable  to  consider  higher  doses  when  treatment  is
tarted  after  the  5th  day  of  life,  due  to  the  drug  pharma-
okinetics,  it  was  not  possible  to  analyze  this  in  the  present
tudy  due  to  the  small  number  of  assessed  patients.  Ran-
omized  prospective  studies  could  further  elucidate  this
ssue.
This  study  showed  no  beneﬁt  in  changing  the  ibuprofen
ose  regimen  to  double  doses  for  the  treatment  of  symp-
omatic  PDA  in  preterm  newborns.  There  was  no  signiﬁcant
ifference  when  comparing  the  two  treatment  dose  regi-
ens.
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